Eton Pharmaceuticals licensed Baylor's IGF-1 patent rights to develop ET-900, extending INCREL for infantile and epileptic ...

Karyopharm files Chapter 11 and names Ayrmid lead bidder in a court-supervised sale. Read how Ayrmid's bid affects its marketed drugs, pipeline and team.

AbbVie expands its Brise migraine license with two preclinical programs worth up to $757M. Read the deal details and what it means for migraine patients.

Sun Pharma's Ilumya (tildrakizumab-asmn) is now FDA-approved for adults with active psoriatic arthritis. Learn how this expands its psoriasis use today.

EMA and Japan's MHLW accept savolitinib plus osimertinib filings for MET-driven EGFR lung cancer. Read the full details on this regulatory milestone today.

Qure's AMT-130 Huntington's gene therapy has FDA Priority Review under Accelerated Approval, with a May 1, 2027 decision date. Read the details now.

Theriva Biologics sells its SYN-004 (ribaxamase) enzyme portfolio to Biossil: $350,000 upfront, up to $91M in milestones. Read the full deal details now.

InventisBio's nomelcitinib met its primary goal in a Phase III psoriasis trial. Read the topline results and the ongoing head-to-head study details now.

FDA pushes back mitapivat sickle cell disease sNDA decision to February 1, 2027. Read how the REMS review affects Agios' PYRUKYND and what comes next.

Teva ends its Phase II TOPAS-MSA emrusolmin trial in multiple system atrophy after a futility analysis. Read now to see what it means for MSA patients.

FDA clears US IND for Alphamab's dual-payload EGFR/HER3 ADC JSKN021, opening its first trial outside China. Read on to learn ...

Leads Biolabs dosed the first lupus patient in its Phase I LBL-047 trial, marking the fusion protein’s first use in ...